联拓生物CNTB财报
Nasdaq
联拓生物是一家临床阶段的全球性生物制药企业，专注于研发针对炎症、免疫及自身免疫类疾病的创新靶向疗法，核心管线覆盖哮喘、特应性皮炎等存在未满足医疗需求的适应症，业务布局覆盖中美及全球主要市场。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Panacea Innovation Limited | 24.30% | 13.4M | ▲ +2.50pp | 2024-07-01 |
| Zheng Wei | 11.70% | 6.5M | — | 2024-02-13 |
| BioFortune Inc. | 11.20% | 6.2M | — | 2024-02-13 |
| RA Capital Management, L.P. | 0.00% | 207.5M | ▼ -5.60pp | 2024-02-27 |
| Panacea Opportunity Fund I, L.P. | 0.00% | 207.5M | — | 2023-10-04 |
内部人交易
Net 90d: +$4.00M · buys $4.00M / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | Director | Grant | 2.8K | $0.00 | $0 |
| 2026-03-31 | LIU JEAN I | Director | Grant | 5.1K | $0.00 | $0 |
| 2026-03-31 | James Huang | Director | Buy (open market) | 1.16M | $3.45 | $4.00M |
1–3 of 3